Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections

Detalhes bibliográficos
Autor(a) principal: Lemos, V
Data de Publicação: 2015
Outros Autores: Cabugueira, A, Noronha, M, Abegão Pinto, L, Reina, M, Branco, J, Gomes, T
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/2062
Resumo: PURPOSE: The aim of the this study was to determine the effect of intravitreal antivascular endothelial growth factor injections on intraocular pressure (IOP) and identify possible risk factors for the development of increased IOP. MATERIALS AND METHODS: This prospective study included a total of 106 eyes receiving intravitreal injection of bevacizumab as treatment for macular edema or active choroidal neovascularization. IOP was measured by Goldmann applanation tonometry immediately before the intravitreal injection and 5 min, 1 h and 15 days after the procedure. The records of the study patients were reviewed for age, gender, history of glaucoma, diabetes mellitus, phakic status, systemic and topical medication and number of previous injections. Subconjunctival reflux was registered. IOP elevation was defined as IOP ≥21 mm Hg and/or a change from baseline of ≥5 mm Hg recorded at least on two or more measurements on the same visit. RESULTS: Mean preoperative IOP was 15.31 ± 3.90 mm Hg and postoperative IOP values were 27.27 ± 11.87 mm Hg (after 5 min), 17.59 ± 6.24 mm Hg (after 1 h) and 16.86 ± 3.62 mm Hg (after 15 days). The IOP variation was statistically significant between pre- and postoperative measurements (p < 0.05). Subconjunctival reflux was recorded in 11.3%, and in this subgroup the IOP at 5 min and at 1 h was lower than preoperative IOP (p < 0.05). CONCLUSIONS: More than one third of the eyes achieved IOPs >30 mm Hg 5 min after injection. Subconjunctival reflux contributed to a lower mean postoperative IOP (p < 0.05). Considerations for the management include prophylactic IOP lowering with medical therapy and/or preinjection ocular decompression for patients with a history of glaucoma or ocular hypertension and switching to an as-needed injection protocol in patients suffering a marked IOP rise in previous injections. © 2015 S. Karger AG, Basel.
id RCAP_bc5347ef81950a931f04581978322aff
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/2062
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor InjectionsCHLC OFTAngiogenesis Inhibitors/therapeutic useBevacizumab/therapeutic useChoroidal Neovascularization/drug therapyIntraocular Pressure/drug effectsIntravitreal InjectionsMacular Edema/drug therapyProspective StudiesRisk FactorsTonometry, OcularVascular Endothelial Growth Factor A/antagonists & inhibitorsAged, 80 and overAdultAgedPURPOSE: The aim of the this study was to determine the effect of intravitreal antivascular endothelial growth factor injections on intraocular pressure (IOP) and identify possible risk factors for the development of increased IOP. MATERIALS AND METHODS: This prospective study included a total of 106 eyes receiving intravitreal injection of bevacizumab as treatment for macular edema or active choroidal neovascularization. IOP was measured by Goldmann applanation tonometry immediately before the intravitreal injection and 5 min, 1 h and 15 days after the procedure. The records of the study patients were reviewed for age, gender, history of glaucoma, diabetes mellitus, phakic status, systemic and topical medication and number of previous injections. Subconjunctival reflux was registered. IOP elevation was defined as IOP ≥21 mm Hg and/or a change from baseline of ≥5 mm Hg recorded at least on two or more measurements on the same visit. RESULTS: Mean preoperative IOP was 15.31 ± 3.90 mm Hg and postoperative IOP values were 27.27 ± 11.87 mm Hg (after 5 min), 17.59 ± 6.24 mm Hg (after 1 h) and 16.86 ± 3.62 mm Hg (after 15 days). The IOP variation was statistically significant between pre- and postoperative measurements (p < 0.05). Subconjunctival reflux was recorded in 11.3%, and in this subgroup the IOP at 5 min and at 1 h was lower than preoperative IOP (p < 0.05). CONCLUSIONS: More than one third of the eyes achieved IOPs >30 mm Hg 5 min after injection. Subconjunctival reflux contributed to a lower mean postoperative IOP (p < 0.05). Considerations for the management include prophylactic IOP lowering with medical therapy and/or preinjection ocular decompression for patients with a history of glaucoma or ocular hypertension and switching to an as-needed injection protocol in patients suffering a marked IOP rise in previous injections. © 2015 S. Karger AG, Basel.KargerRepositório do Centro Hospitalar Universitário de Lisboa Central, EPELemos, VCabugueira, ANoronha, MAbegão Pinto, LReina, MBranco, JGomes, T2015-03-24T10:52:35Z20152015-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2062engOphthalmologica. 2015 Mar 13. [Epub ahead of print]info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:34:38Zoai:repositorio.chlc.min-saude.pt:10400.17/2062Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:19:27.686557Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
title Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
spellingShingle Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
Lemos, V
CHLC OFT
Angiogenesis Inhibitors/therapeutic use
Bevacizumab/therapeutic use
Choroidal Neovascularization/drug therapy
Intraocular Pressure/drug effects
Intravitreal Injections
Macular Edema/drug therapy
Prospective Studies
Risk Factors
Tonometry, Ocular
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Aged, 80 and over
Adult
Aged
title_short Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
title_full Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
title_fullStr Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
title_full_unstemmed Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
title_sort Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections
author Lemos, V
author_facet Lemos, V
Cabugueira, A
Noronha, M
Abegão Pinto, L
Reina, M
Branco, J
Gomes, T
author_role author
author2 Cabugueira, A
Noronha, M
Abegão Pinto, L
Reina, M
Branco, J
Gomes, T
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Lemos, V
Cabugueira, A
Noronha, M
Abegão Pinto, L
Reina, M
Branco, J
Gomes, T
dc.subject.por.fl_str_mv CHLC OFT
Angiogenesis Inhibitors/therapeutic use
Bevacizumab/therapeutic use
Choroidal Neovascularization/drug therapy
Intraocular Pressure/drug effects
Intravitreal Injections
Macular Edema/drug therapy
Prospective Studies
Risk Factors
Tonometry, Ocular
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Aged, 80 and over
Adult
Aged
topic CHLC OFT
Angiogenesis Inhibitors/therapeutic use
Bevacizumab/therapeutic use
Choroidal Neovascularization/drug therapy
Intraocular Pressure/drug effects
Intravitreal Injections
Macular Edema/drug therapy
Prospective Studies
Risk Factors
Tonometry, Ocular
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Aged, 80 and over
Adult
Aged
description PURPOSE: The aim of the this study was to determine the effect of intravitreal antivascular endothelial growth factor injections on intraocular pressure (IOP) and identify possible risk factors for the development of increased IOP. MATERIALS AND METHODS: This prospective study included a total of 106 eyes receiving intravitreal injection of bevacizumab as treatment for macular edema or active choroidal neovascularization. IOP was measured by Goldmann applanation tonometry immediately before the intravitreal injection and 5 min, 1 h and 15 days after the procedure. The records of the study patients were reviewed for age, gender, history of glaucoma, diabetes mellitus, phakic status, systemic and topical medication and number of previous injections. Subconjunctival reflux was registered. IOP elevation was defined as IOP ≥21 mm Hg and/or a change from baseline of ≥5 mm Hg recorded at least on two or more measurements on the same visit. RESULTS: Mean preoperative IOP was 15.31 ± 3.90 mm Hg and postoperative IOP values were 27.27 ± 11.87 mm Hg (after 5 min), 17.59 ± 6.24 mm Hg (after 1 h) and 16.86 ± 3.62 mm Hg (after 15 days). The IOP variation was statistically significant between pre- and postoperative measurements (p < 0.05). Subconjunctival reflux was recorded in 11.3%, and in this subgroup the IOP at 5 min and at 1 h was lower than preoperative IOP (p < 0.05). CONCLUSIONS: More than one third of the eyes achieved IOPs >30 mm Hg 5 min after injection. Subconjunctival reflux contributed to a lower mean postoperative IOP (p < 0.05). Considerations for the management include prophylactic IOP lowering with medical therapy and/or preinjection ocular decompression for patients with a history of glaucoma or ocular hypertension and switching to an as-needed injection protocol in patients suffering a marked IOP rise in previous injections. © 2015 S. Karger AG, Basel.
publishDate 2015
dc.date.none.fl_str_mv 2015-03-24T10:52:35Z
2015
2015-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/2062
url http://hdl.handle.net/10400.17/2062
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Ophthalmologica. 2015 Mar 13. [Epub ahead of print]
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Karger
publisher.none.fl_str_mv Karger
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131292050128896